Abstract CT022: First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterationsTimothy A. Yap, Alison M. Schram, Elisa Fontana et al.|Cancer Research|2026Cited by 0